Relevant bibliographies by topics / DurTvå

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'DurTvå'

Author: Grafiati
Published: 4 June 2021
Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'DurTvå.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "DurTvå"

1

Rancour-Laferriere, Daniel. "Nadežda Durova Remembers her Parents." Russian Literature 44, no. 4 (November 1998): 457–68. http://dx.doi.org/10.1016/s0304-3479(98)80002-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

López, Camila Soares. "“Durtal”, de Paul Valéry: uma tradução." Rónai – Revista de Estudos Clássicos e Tradutórios 7, no. 2 (December 11, 2019): 151–59. http://dx.doi.org/10.34019/2318-3446.2019.v7.25968.

Full text
Abstract:
Neste trabalho, propomos uma tradução do ensaio crítico “Durtal”, de autoria de Paul Valéry e que versa sobre o romance homônimo de J.-K. Huysmans. Originalmente, o texto de Valéry foi publicado em 1898 na revista Mercure de France, petite revue parisiense que circulou nos meios simbolistas e de demais entusiastas da renovação literária. Em um primeiro momento, tecemos considerações acerca dos dois autores, bem como sobre a proximidade de ambos. Por fim, apresentamos a tradução de “Durtal” para língua portuguesa.
APA, Harvard, Vancouver, ISO, and other styles
3

Wojciech, Jernajczyk, and Leszek Jerzy. "EEG SLEEP PATTERN DURTNG INTERFERON TREATMENT." Clinical Neuropharmacology 15 (1992): 276B. http://dx.doi.org/10.1097/00002826-199202001-00533.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Goldman, Jonathan Wade, Sarina Anne Piha-Paul, Brendan D. Curti, Katrina Pedersen, Todd Michael Bauer, Stefanie L. Groenland, Richard D. Carvajal, et al. "Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 3003. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3003.

Full text
Abstract:
3003 Background: We report safety and tolerability of MEDI0562, a humanized IgG1κ OX40 monoclonal antibody (mAb), in combination with durvalumab (durva; anti-PD-L1 mAb) or tremelimumab (treme; anti-CTLA-4 mAb) in patients (pts) with previously treated advanced solid tumors. Methods: In this phase 1, open-label study (NCT02705482), adult pts received escalating doses of MEDI0562 (2.25, 7.5 or 22.5 mg/kg) every 2 wks (Q2W) in combination with durva (1500 mg/kg) or treme (75 or 225 mg/kg) Q4W, until confirmed disease progression or unacceptable toxicity. Tumor assessments were performed Q8W with immune-related Response Evaluation Criteria in Solid Tumors. Results: In total, 27 and 31 pts received MEDI0562 + durva or treme, across 5 dose combination cohorts (3 + 3 design), with a maximum tolerated dose of 7.5 mg MEDI0652 + 1500 mg durva and maximum administered dose of 10 mg MEDI0562 + 225 mg treme. Median duration of exposure was 12.0 (range 2.0–80.9) and 8.0 (range 2.0–42.0) wks, respectively. Two (22.5 mg MEDI10562 + durva) and 3 (2.25 mg MEDI0652 + 225 mg treme, 22.5 mg MEDI0562 + 75 and 225 mg treme) dose limiting toxicities were observed. For MEDI0562 + durva and MEDI0562 + treme groups respectively, treatment-emergent adverse events (TEAEs) were reported in 96.3% and 100% of pts; most common TEAEs were fatigue (55.6%) and pruritus (45.2%), Gr 3/4 TEAEs occurred in 74.1% and 67.7%; and MEDI0562-related AEs were reported in 20 (74.1%) and 24 (77.4%) pts. Six TEAEs in each group led to MEDI0562 discontinuation (22.2% and 19.4%, respectively), 2 led to death (renal failure [7.5 mg MEDI0562 + durva], multiple organ dysfunction syndrome [22.5 mg MEDI0562 + 225 mg treme]). Three response evaluable pts had PR (11.5% [7.5 and 22.5 mg MEDI0562 + durva, n = 26]). Median overall survival was 17.4 and 11.9 mos for MEDI0562 + durva and MEDI0562 + treme, with stable disease seen in 9 pts from each group, 34.6% vs 29.0%, respectively. Serum exposure of MEDI0562 increased dose proportionally. Post treatment serum antidrug antibody (ADA) was detected in 20 pts from MEDI0562 + durva and MEDI0562 + treme (74.1% and 71.4%, respectively). The impact of ADA on MEDI0562 pharmacokinetics was seen at all doses. Mean percentage of Ki67+CD4+ and Ki67+CD8+ memory T cells increased, while mean percentage of OX40+CD4+ memory T cells decreased following the first dose of MEDI0562 + durva or treme. Conclusions: The safety profile of MEDI0562 in combination with durva or treme was similar between groups. Clinical activity was observed with MEDI0562 + durva in pts with advanced solid tumors. Clinical trial information: NCT02705482 .
APA, Harvard, Vancouver, ISO, and other styles
5

Naidoo, Jarushka, Johan F. Vansteenkiste, Corinne Faivre-Finn, Mustafa Özgüroğlu, Shuji Murakami, Rina Hui, Xavier Quantin, et al. "Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC)." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 9048. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.9048.

Full text
Abstract:
9048 Background: The phase 3 PACIFIC trial established durvalumab (durva) after chemoradiotherapy (CRT) as SoC for pts with unresectable stage III NSCLC. We report exploratory analyses to characterize non-pneumonitis (np) imAEs that occurred with durva in PACIFIC. Methods: PACIFIC was a double blind trial of pts without disease progression after platinum-based concurrent CRT (≥2 cycles). Pts were randomized 2:1 to receive durva 10 mg/kg or placebo (pbo) IV q2w for ≤12 months, stratified by age, sex and smoking history. We characterized the time to onset, duration, and management/outcomes of np imAEs and their association with (1) baseline pt/disease factors and (2) AEs (excluding all-cause pneumonitis). Results: Of 709 treated pts, 19% and 11% experienced imAEs and np imAEs of any grade, respectively; proportionally more had np imAEs with durva (71/475; 15%) vs pbo (5/234; 2%). Thyroid disorders (54/475; 11%), rash/dermatitis (9/475; 2%), and diarrhea/colitis (5/475; 1%) were the most common np imAEs with durva; rash/dermatitis had the shortest time to onset (Table). Among durva treated pts with np imAEs, 11% had grade 3/4 np imAEs, 41% had np imAEs that resolved, and none had fatal np imAEs; interventions included endocrine replacement therapy (73%), systemic corticosteroids (34%), high dose corticosteroids (16%), and discontinuation (10%). There were no apparent differences in baseline factors between pts with or without np imAEs. Durva had a broadly manageable safety profile irrespective of the occurrence of np imAEs. However, a higher proportion of durva treated pts with vs without np imAEs experienced all-cause, grade 3/4 events (41% vs 29%); none were fatal (excl. pneumonitis). Conclusions: Np imAEs occurred infrequently in PACIFIC, but were more common with durva vs pbo; thyroid disorders and rash/dermatitis were the most common np imAEs. Of durva treated pts with np imAEs, 11% experienced np imAEs of grade 3/4. Overall, np imAEs were broadly manageable and did not lead to high rates of discontinuation, and no association with baseline factors was seen, suggesting this should not deter use of durva in eligible pts. Clinical trial information: NCT02125461. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
6

Planchard, David, Byoung Chul Cho, Jhanelle Elaine Gray, Luis G. Paz-Ares, Mustafa Ozguroglu, Augusto E. Villegas, Davey B. Daniel, et al. "First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): 9054. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.9054.

Full text
Abstract:
9054 Background: In the phase 3 PACIFIC trial of unresectable, stage III NSCLC patients (pts) without progression after concurrent chemoradiotherapy (cCRT), durvalumab (durva) significantly improved PFS and OS with similar safety compared to placebo (pbo). We performed exploratory analyses to characterize first subsequent treatment (Tx) after discontinuation of durva. Methods: Pts with WHO PS 0/1 and any tumor PD-L1 status were randomized (2:1) 1–42 days after ≥2 cycles of platinum-based cCRT to durva 10 mg/kg IV or pbo Q2W up to 12 months, stratified by age, sex and smoking history. Pts were classified by the use or not of first subsequent Tx and category of first systemic Tx (platinum doublet CT [PDCT], single-agent CT [SCT], immunotherapy [IT] or targeted therapy [TT]). Results: As of Mar 22, 2018, 216/476 (45.4%) and 153/237 (64.6%) in the durva and pbo arms, respectively, had a RECIST-based PFS event per BICR (5.7% and 8.4% due to death). 195 (41.0%) and 128 (54.0%) received first subsequent Tx, most of which were systemic Tx (158 [33.2%] and 109 [46.0%]): PDCT (16.4% and 19.0%), SCT (8.6% and 8.4%), IT (4.2% and 13.5%) or TT (3.8% and 5.1%); 7.8% and 8.0% received RT only. Time to first subsequent therapy or death (TFST) was longer with durva vs pbo (HR 0.58; 95% CI 0.47–0.72; median 21.0 vs 10.4 months). Baseline characteristics of pts with or without first subsequent Tx were similar, and similar across durva or pbo arms. Among pts with systemic Tx, baseline characteristics (including pre-cCRT PD-L1 status) were generally similar, except pts on TT, more of whom were EGFR+ (70.0% vs 0–6.6% of other systemic Tx groups) with commonly associated phenotypes (more females, Asians, non-smokers and non-squamous pts). Best overall response to first systemic Tx will be presented. Conclusions: Due to longer PFS and fewer progression events with durva vs pbo, fewer pts on durva required subsequent Tx and, per TFST, much later. With the exception of IT, use of each subsequent Tx was similar between the durva and pbo arms with PDCT the most common. Baseline characteristics were similar for pts with or without first subsequent Tx and pts who received first systemic Tx, except for pts who received TT, as expected due to their molecular profile.
APA, Harvard, Vancouver, ISO, and other styles
7

Sibourg, Eléonore. "Retrouver le temple du sacré : la logique des extrêmes dans le roman de Durtal." Quêtes littéraires, no. 3 (December 30, 2013): 108–15. http://dx.doi.org/10.31743/ql.4611.

Full text
Abstract:
In the late 19th century a reversal of the values linked to the sacred and the profane can be observed. As Religion retreats, Positivism and faith in Progress fill the gap left by the abandoned spiritual belief. A nostalgia for transcendence arises amongst writers. Naturalism turns out to be sterile, but, sill, a belief in God seems to have become impossible. It is in this context that Huysmans writes his novels. The Durtal tetralogy in particular focuses on this theme: desperate, the main character wanders around Catholicism, seeking a sense of the Sacred. He first explores the world of Satanism before the conversion. But even when faith is regained, problems are not solved. In the religious domain itself, Durtal condemns the sacralization of the profane. Henceforth, the Durtal tetralogy manifests itself as a novel of the in-between: from brothel to church, between up-above and down-below, between almighty materialism and bourgeois Catholicism, this misanthropic writer prays for a renewed and primitive form of religious practice in which the individual can access the Sacred again. The quest for the supernatural, through a questioning of contemporary society, becomes a quest for Identity.
APA, Harvard, Vancouver, ISO, and other styles
8

Richardson, Paul G., William Bensinger, Katja C. Weisel, Kevin Boyd, Karthik Ramasamy, Esther Gonzalez, Linda Favre-Kontula, et al. "Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM)." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): TPS8054. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.tps8054.

Full text
Abstract:
TPS8054 Background: DARA, a monoclonal antibody (mAb) against CD38, is approved for RRMM. Combination treatment (Tx) with DARA + DURVA, a mAb against programmed death ligand-1 (PD-L1), may enhance host anti-MM immunity and response. DARA and PD-L1 mAbs have each demonstrated clinical activity in combination with pomalidomide (POM) + low-dose dexamethasone (LoDEX) in MM. Thus, the phase 2 MEDI4736-MM-003 trial is evaluating DURVA + DARA in RRMM, and, in an exploratory analysis, the addition of POM + LoDEX to DARA + DURVA either upon progressive disease (PD) with DARA + DURVA or as up-front Tx will be assessed. Methods: ≈ 144 pts with RRMM are being enrolled. Pts with measurable MM who received ≥ 3 prior anti-MM Txs, including a protease inhibitor and an immunomodulatory agent, or are double-refractory to these 2 agents will be included. Exclusion criteria include allogeneic stem cell transplant (SCT), autologous SCT ≤ 12 weeks, and prior DARA or other CD38 antibody therapies. Primary endpoints are overall response rate (ORR) and safety. Secondary endpoints are time to response, duration of response, progression-free survival, and pharmacokinetics. The study includes a 3 + 3 safety run-in phase to confirm the tolerability of the recommended phase 2 doses (RP2Ds) of DURVA and DARA. Dose-limiting toxicities will be evaluated during the first Tx cycle. Safety and efficacy will be assessed by a Simon 2-stage design (Table). POM + LoDEX may be added to DARA + DURVA in pts who received ≥ 2 cycles of DARA + DURVA and had confirmed PD. Based on preliminary safety and efficacy, the 4-drug regimen may be explored as up-front Tx. Tx with either the 2- or 4-drug regimens will continue until PD or unacceptable toxicity. Pts treated with POM will be followed for second primary malignancies every 6 mos until the end of the trial. To date, 6 pts have enrolled in the run-in phase. Clinical trial information: NCT02807454. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
9

Joshi, Monika, Matthew Kaag, Leonard Tuanquin, Jason Liao, Deepak Kilari, Hamid Emamekhoo, Alexander Sankin, et al. "Phase II clinical study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results for primary analyses and survival. BTCRC-GU15-023." Journal of Clinical Oncology 39, no. 6_suppl (February 20, 2021): 398. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.398.

Full text
Abstract:
398 Background: Bladder cancer (BC) patients (pts) who are cisplatin ineligible/unfit for surgery, or locally advanced and unresectable have limited treatment options. DUART investigates if the combination of radiation therapy (RT) and checkpoint inhibitor, durvalumab (durva) is safe and effective in these pts. We recently reported that the combination was safe, tolerable and disease control rate (DCR) was 92% post durvaRT. Here we present interim efficacy data of our phase II study. Methods: Pts with pure or mixed urothelial bladder cancer (T2-4 N0-2 M0) were enrolled if their tumor was unresectable (35%), were unfit for surgery (50%) and/or cisplatin ineligible (89%). Primary endpoints: a) PFS at 1-yr b) DCR post adjuvant durva; Secondary endpoints: a) CR post durvaRT b) median PFS c) median OS. Pts were treated with durva (1500mg) Q4 wks x2 doses along with definitive RT (64.8Gy, 36 fractions over 7 wks) to the bladder and involved nodes followed by adjuvant durva Q4 wks x 1 yr. Response was evaluated with CT scan and cystoscopy+biopsy. Sample size was based on assumption that this regimen would increase 1 yr PFS by 25% compared to RT alone (50% to 75%); we assumed DCR of 75%. A total of 26 pts were needed to reach a statistical power of at least 80% at one-sided alpha of 5% and to allow for 10% drop out rate. Results: Twenty-six pts (19 males, 7 females) were enrolled, median age 74 yr (51-94). Sixty two percent of pts had >T2 disease, 31% had positive lymph nodes; 62% with unresectable tumor or were unfit for surgery due to comorbidities. At data cut off (9/30/2020) 20/26 pts were evaluable for DCR post adjuvant durva (3 pts with CR post durvaRT, did not get adjuvant therapy; 1 pt withdrew after 3 cycles for adjuvant durva and was on f/u with unconfirmed CR; 2 pts are still on adjuvant durva) and 25/26 for PFS and all 26 pts for OS. Post completion of adjuvant durva, DCR was seen in 70 % (14/20 with 10 CR; 3 PR; 1 SD; 6 PD). One-year probability of PFS was 73% (95% CI 56.4%, 94.4%), median PFS was 18.5 months. One-year OS probability was 83.8% (95% CI 70.4%, 99.7%) with two-year OS probability of 76.8 (95% CI 60.2%, 98%). Median OS has not been reached. We did not observe any correlation between clinical outcome and baseline tumor PD-L1 expression. Conclusions: DurvaRT followed by adjuvant durva demonstrated promising efficacy with 1-year PFS probability of 73%, 1- year OS probability of 83.8% and DCR of 70% in MIBC and locally advanced BC pts with comorbidities. Results will be updated prior to the final presentation. Efficacy was also seen in node (+) pts which led to the design of prospective randomized NCTN study. Induction chemo followed by chemo+durvaRT+ adjuvant durva vs. chemoRT combination is being evaluated in the ongoing EA8185 clinical trial (ECOG-ACRIN/NRG study) for node (+) BC pts. Clinical trial information: NCT02891161.
APA, Harvard, Vancouver, ISO, and other styles
10

Rozgonyi, Nikoletta. "Effect of air pollution on coarse-grained limestone." Epitoanyag - Journal of Silicate Based and Composite Materials 54, no. 2 (2002): 30–36. http://dx.doi.org/10.14382/epitoanyag-jsbcm.2002.6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "DurTvå"

1

Hertzberg, Bulat Alexandra, and Maria Brander. "Hur tänkte Polisen när de tänkte fel? : En kvalitativ studie om vilka faktorer som bidrog till att Polisens UtredningsStöd PUST Siebel lades ned." Thesis, Högskolan i Borås, Akademin för vård, arbetsliv och välfärd, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:hb:diva-3309.

Full text
Abstract:
Mellan september 2010 till augusti 2011 påbörjade Polisen ett införande av ett nytt utredningsstöd, PUST (Polisens UtredningsStöd). Syftet med detta var att det skulle effektivisera avrapporteringen och att fler poliser skulle bli mer synliga ute i samhället. Systemet PUST med plattformen Java ansågs vara framgångsrikt men efter endast ett par månaders användning togs ett beslut av polisledningen att plattformen skulle bytas ut och ersättas med ett standardsystem, PUST Siebel. Till skillnad från Java fick Siebel en enorm kritik då det upplevdes svårhanterligt och komplicerat att arbeta i. I februari 2014 togs beslutet att PUST Siebel skulle avvecklas.Detta ledde till att vi formulerade frågeställningen; Vilka faktorer bidrog till att PUST Siebel lades ned?För att kunna besvara vår forskningsfråga genomförde vi en kvalitativ studie där utgångspunkten var att undersöka den problematik som kan uppstå vid implementeringen av ett större IT-system i offentlig sektor. Vi har genomfört intervjuer med sex representanter från Polismyndigheten i Göteborg, Borås och Jönköping. Samtliga respondenter har arbetat i PUST Siebel, vilka var relevanta för vår undersökning. Huvudinriktningen i vår studie är hur användbarhet och handlingsbarhet påverkar införandet av ett större IT-system.Tidigare forskning som har gjorts om införande av IT-system har visat att användbarhet och handlingsbarhet ofta prioriteras bort. En orsak till det är att det saknas kunskap om dessa begrepp, vilket medför att det inte går att förstå användarnas behov. Enligt författarna Lind m.fl. (2011) kan konsekvensen bli att det skapas ett ologiskt system som inte blir hållbart i längden.Resultatet i vår studie visar att användbarhet och handlingsbarhet är viktiga komponenter att ta hänsyn till vid införandet av ett IT-system. När ett IT-system skall införas skall det utvecklas på ett sådant sätt att det främst gynnar användarna. De bidragande faktorerna till att PUST Siebel avvecklades var bland annat att systemet inte var komplett när det infördes i verksamheten, vilket bidrog till att användarna uppfattade systemet som ologiskt och komplicerat att arbeta i. En annan bidragande orsak till nedläggningen var att det fattades ett felaktigt beslut om att byta till ett standardsystem då det senare skulle visa sig att det saknades teknisk kompetens om hur ett sådant system fungerar och är uppbyggt.
Between September 2010 and August 2011, the Swedish Police force began to implement a new investigation support system, PUST (Polisens UtredningsStöd). The purpose of this was to make debriefing more efficient and thereby enable more police officers to be visible out on the streets. The system was considered successful when using the platform Java, however, after only a few months the decision was taken by the Police management to replace the platform by a standard system, PUST Siebel. Unlike Java, Siebel was harshly criticised as it was perceived to be cumbersome and complicated to use. Then, in February 2014, the decision was taken to shut down PUST Siebel.This led to us formulating the question; Which factors led to PUST Siebel being discontinued?To be able to answer our research question we carried out a qualitative study where the starting point was to look into the problems that can arise when implementing a larger IT- system in the public sector. We interviewed six representatives from the Police Department in Gothenburg, Borås and Jönköping. All of the respondents had direct experience of working with PUST Siebel. The main focus of our study is how usability and actability affect the implementation of a larger IT- system.Previous research has shown that usability and actability are often deprioritised when an IT- system is developed. One reason is that there is a lack of knowledge regarding these aspects, which means that the needs of the users are not fully understood. The authors Lind et (2011) says that one consequence of this could be that the system created is illogical and not sustainable long term. The result of our study shows that usability and actability are important aspects to consider when implementing an IT- system. When an IT-system is due to be implemented it should be developed in such a way so that it benefits the users.One contributing factor that led to PUST Siebel being discontinued was that the system not was complete when it was introduced into the business, which led to the users perceived the system as illogical and difficult to work in. Another contributing factor to the demise was that it was made a wrong decision about switching to a standard system where it subsequently turns out that there was no technical skills on how such a system works and is structured. This study is written in swedish.
APA, Harvard, Vancouver, ISO, and other styles
2

Sibourg, Eléonore. "Science et surnaturel dans le cycle de Durtal de Huysmans." Thesis, University of Kent, 2015. https://kar.kent.ac.uk/52949/.

Full text
Abstract:
This thesis examines interactions between science and the supernatural in Huysmans’s Durtal tetralogy. The protagonist, whose aesthetic and philosophical starting point is naturalism, converts to Catholicism. This unusual conversion reflects social upheavals contemporary with Huysmans’s cycle of novels. In the late nineteenth century, science, emerging as symbol of new hope and salvation for humanity, has in a sense replaced religion. The Durtal cycle catalogues the disorders generated by this replacement, and represents the creation of a new order more suited to Durtal’s persona, through deconstruction of existing codes and beliefs. Thus is shaped the intellectual and aesthetic matrix of the four novels. Pathology is at the intersection of the interactions between science and the supernatural, the various components of which constitute the subject of the three substantive chapters of the thesis. Figuring social degeneration and the creation of imaginary medical worlds founded on contamination, Huysmans’s text explores the boundaries between science and religion, thus offering a new cosmogony constructed around a concept of mystic substitution associated with Catholicism. Analysis of these textual explorations is followed by a study of the body and the soul as the two primary principles contributing to the conflicts articulated in Huysmans’s work. The conversion processes to which the body and the soul are subjected help to build renewed relationships between the material and the spiritual, the visible and the invisible. Writing thus appears as the result of an alchemical quest in which opposites can ultimately be reunited. The thesis concludes with a discussion of the development of the novel form, subject to so many contradictory influences. The pharmaceutical quality – in Derridean terms – of writing ends this crisis and restores the author’s authority, making of the Durtal tetralogy a work that is characterised at one and the same time by its naturalism and by its mysticism.
APA, Harvard, Vancouver, ISO, and other styles
3

Sibourg, Éléonore. "Science et surnaturel dans le cycle de Durtal de Huysmans." Thesis, Paris 4, 2015. http://www.theses.fr/2015PA040074.

Full text
Abstract:
Cette étude examine les interactions de la science et du surnaturel dans le cycle de Durtal, de Huysmans. Le protagoniste, parti du naturalisme, se convertit au catholicisme. Cette étrange conversion reflète les renversements à l’œuvre dans la société contemporaine. À la fin du XIXe siècle, la science, figurant le salut et l’espoir de l’humanité, s’est substituée à la religion. Le cycle de Durtal expose les désordres générés par cette inversion. Il s’agit alors de déconstruire les savoirs et les croyances en vigueur afin de forger un ordre qui correspondra enfin au protagoniste : telle est la matrice de ces romans. La pathologie devient l’interface privilégiée de ces interactions, dont les déclinaisons constituent l’objet de nos trois parties. Dégénérescence sociale, création d'imaginaires médicaux portés par la contamination, le texte travaille les frontières entre science et religion, proposant ainsi une nouvelle cosmogonie érigée autour du concept de substitution mystique, propre à la religion catholique. Nous analysons ensuite les principes à l’origine des conflits évoqués: les conversions de l’âme et du corps amènent à fonder à nouveau les relations entre le matériel et le spirituel, le visible et l'invisible. L'écriture apparaît ainsi comme le produit d'une quête alchimique, où les contraires peuvent enfin être réunis. Nous traitons enfin du devenir du roman, déformé par tant d’influences contraires. Le caractère pharmaceutique de l'écriture (Jacques Derrida) met fin à cette crise, et redonne à l'auteur son autorité, faisant du roman de Durtal une œuvre naturaliste et mystique
This thesis examines interactions between science and the supernatural in Huysmans’s Durtal tetralogy. The protagonist, whose aesthetic and philosophical starting point is naturalism, converts to Catholicism. This unusual conversion reflects social upheavals contemporary with Huysmans’s cycle of novels. In the late nineteenth century, science, emerging as symbol of new hope and salvation for humanity, has in a sense replaced religion. The Durtal cycle catalogues the disorders generated by this replacement, and represents the creation of a new order more suited to Durtal’s persona, through deconstruction of existing codes and beliefs. Thus is shaped the intellectual and aesthetic matrix of the four novels. Pathology is at the intersection of the interactions between science and the supernatural, the various components of which constitute the subject of the three substantive chapters of the thesis. Figuring social degeneration and the creation of imaginary medical worlds founded on contamination, Huysmans’s text explores the boundaries between science and religion, thus offering a new cosmogony constructed around a concept of mystic substitution associated with Catholicism. Analysis of these textual explorations is followed by a study of the body and the soul as the two primary principles contributing to the conflicts articulated in Huysmans’s work. The conversion processes to which the body and the soul are subjected help to build renewed relationships between the material and the spiritual, the visible and the invisible. Writing thus appears as the result of an alchemical quest in which opposites can ultimately be reunited. The thesis concludes with a discussion of the development of the novel form, subject to so many contradictory influences. The pharmaceutical quality – in Derridean terms – of writing ends this crisis and restores the author’s authority, making of the Durtal tetralogy a work that is characterised at one and the same time by its naturalism and by its mysticism
APA, Harvard, Vancouver, ISO, and other styles
4

Vendries, Bray Ernesto [Verfasser], Werner [Akademischer Betreuer] Durth, and Eckhart [Akademischer Betreuer] Ribbeck. "Leopold Rother und die moderne Bewegung in Kolumbien / Ernesto Vendries Bray. Betreuer: Werner Durth ; Eckhart Ribbeck." Darmstadt : Universitäts- und Landesbibliothek Darmstadt, 2014. http://d-nb.info/1110792018/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Durov, Nikolai [Verfasser]. "New approach to Arakelov geometry / vorgelegt von Nikolai Durov." 2007. http://d-nb.info/984972536/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "DurTvå"

1

Llais y durtur: Storïau. Llandysul, Dyfed: Gomer, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sackett, Colin. Durov e ego dressirovannbie zhivotnbie =: Durov and his performing animals. London: White Lies Publications, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Newell, L. E. Durty south grind: A novel. New York: Strebor Books, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kod Durova: Realʹna︠i︡a istori︠i︡a "VKontakte" i ee sozdatel︠i︡a. Moskva: Izd-vo "Mann, Ivanov i Farber", 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Arman, A. Bi ėmėgtėĭ khu̇nd durtaĭ: Dig thou, women : khaĭryn songodog ȯgu̇u̇llėg. [Ulaanbaatar]: A. Arman, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chuluunt︠s︡ėt︠s︡ėg, Ch. Zaraany khu̇u̇ bȯȯdiĭ ėkhdėė l zȯȯlȯn: [amʹtand durtaĭ khėn bu̇khėnd zoriulav. Ulaanbaatar Khot: Mȯnkhiĭn U̇sėg KhKhK, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hrvatsko društvo za mehaniku. Susret. Zbornik radova: Drugog susreta Hrvatskoga durštva za mehaniku, Split 12.-13. rujna 2008. Split: Hrvatsko društvo za mehaniku, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hrvatsko društvo za mehaniku. Susret. Zbornik radova: Drugog susreta Hrvatskoga durštva za mehaniku, Split 12.-13. rujna 2008. Split: Hrvatsko društvo za mehaniku, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lörincz, Peter. Perceptions languedociennes: Aquarelles, dessins et gravures de Peter Lörincz ; [textes de Anne-Marie Jeanjean, Werner Durth, Stanislav Demidjuk]. [Saint-Jean-de-Fos]: Association Plaisir et culture, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Durova, Natalʹi͡a. Zveri i ptit͡sy--zhiznʹ moi͡a. Moskva: Izd-vo ADP, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "DurTvå"

1

Cheauré, Elisabeth. "Durova, Nadežda (Ps.: A. Aleksandrov; verh. Černova)." In Metzler Autorinnen Lexikon, 149–50. Stuttgart: J.B. Metzler, 1998. http://dx.doi.org/10.1007/978-3-476-03702-2_105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kähler, Gert. "Werner Durth / Niels Gutschow (1988): Träume in Trümmern — Stuttgart." In Architektour, 11–16. Wiesbaden: Vieweg+Teubner Verlag, 1991. http://dx.doi.org/10.1007/978-3-322-83912-1_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"Durtal." In Collected Works of Paul Valery, Volume 9, 269–83. Princeton University Press, 2017. http://dx.doi.org/10.1515/9781400886661-020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"LA CONVERSION DE DURTAL." In Joris-Karl Huysmans, 95–113. Brill | Rodopi, 2003. http://dx.doi.org/10.1163/9789004333536_010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Durth, Werner. "C.7 BaukulturWerner Durth." In Stadtsoziologie und Stadtentwicklung, 527–38. Nomos Verlagsgesellschaft mbH & Co. KG, 2020. http://dx.doi.org/10.5771/9783845276779-527.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"The Palm-Durov Circle." In Dostoevsky, 273–92. Princeton University Press, 2020. http://dx.doi.org/10.2307/j.ctvvh85gv.24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Glaudes, Pierre. "De René à Durtal : individu et communauté au siècle des révolutions." In En quel nom parler ?, 17–33. Presses Universitaires de Bordeaux, 2010. http://dx.doi.org/10.4000/books.pub.7868.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Durt, Christoph. "Consciousness, Culture, and Significance." In Embodiment, Enaction, and Culture. The MIT Press, 2017. http://dx.doi.org/10.7551/mitpress/9780262035552.003.0004.

Full text
Abstract:
The chapter offers a new view on consciousness and culture by investigating their relation to significance. Against the widespread restriction of consciousness to phenomenal aspects and that of culture to “thick description,” Durt argues that consciousness discloses aspects of significance, while culture encompasses shared significance as well as the forms of behavior that enact significance. Significance is intersubjective and constantly re-instantiated in new contexts of relevance rather than belonging to single individuals (cf. Gallagher, this volume). It is embedded in the shared world to which we relate by cultural forms of thinking and sense-making. Bringing together insights on the role of consciousness for the constitution of the world from Husserlian phenomenology with those on cultural forms of behavior by Wittgenstein and Ryle, Durt distinguishes different levels of significance accomplished by embodied consciousness and interaction. He explains that the real issue underlying “hybrid” concepts of the mind does not consist in embodied versus disembodied systems of production (cf. Di Paolo and De Jaegher, this volume), but in different levels of significance accomplished by consciousness and culture. Consciousness is embodied on every level, and it integrates different levels of significance.
APA, Harvard, Vancouver, ISO, and other styles
9

Stahura, R. P. (Dick). "The price of DURT — what fugitive materials cost conveyors and how improved systems can save money." In Materials Handling in Pyrometallurgy, 217–26. Elsevier, 1990. http://dx.doi.org/10.1016/b978-0-08-040414-1.50024-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "DurTvå"

1

Callahan, Margaret K., Kunle Odunsi, Mario Sznol, John Nemunaitis, Patrick A. Ott, Patrick Dillon, Reva Schneider, et al. "Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors." In Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-a006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sabari, Joshua, Kristen Aufiero Ramirez, Paul Schwarzenberger, Toni Ricciardi, Mary Macri, Aileen Ryan, and Ralph Venhaus. "Abstract B209: Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC)." In Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-b209.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zamarin, Dmitriy, Kunle Odunsi, Brian Slomovitz, Vanessa M. Hubbard-Lucey, Danielle McCabe, Lisa Shohara, Paul Schwarzenberger, et al. "Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC)." In Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-a022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Necchi, Andrea, Luigi Mariani, Daniele Raggi, Patrizia Giannatempo, Maurizio Colecchia, Giuseppina Calareso, Roberto Salvioni, Siraj M. Ali, and Jon H. Chung. "Abstract CT102: APACHE: An open label, randomized, phase II study of Durvalumab (Durva), alone or in combination with Tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-ct102.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lee, James J., Greg Yothers, Thomas J. George, Marwan G. Fakih, Atrayee Basu Mallick, Edith P. Mitchell, James L. Wade, et al. "Abstract 2257: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-9." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2257.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lee, James J., Greg Yothers, Thomas J. George, Marwan G. Fakih, Atrayee Basu Mallick, Edith P. Mitchell, James L. Wade, et al. "Abstract 2257: Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-9." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2257.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "DurTvå"

1

Young, D. A., and T. R. C. Aston. 'Durov plot' users guide: computer calculation and plotting of Durov diagrams for water chemistry analysis. Natural Resources Canada/ESS/Scientific and Technical Publishing Services, 1985. http://dx.doi.org/10.4095/304841.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zinck, D., and T. R. C. Aston. Durov plot' users guide: computer calculation plotting of Durov diagrams for water chemistry analysis using the IBMAT. Natural Resources Canada/ESS/Scientific and Technical Publishing Services, 1986. http://dx.doi.org/10.4095/304903.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'DurTvå' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography